Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 13/20 | 0.38 |
| ▸ | KEAP1 | Q14145 | 2/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3549820 | 0.77 | FFAR1 (0.51) | FFAR1KEAP1 | |
| SCHEMBL14286031 | 0.74 | FFAR1 (0.56) | FFAR1 | |
| SCHEMBL3549582 | 0.74 | FFAR1 (0.56) | FFAR1 | |
| Propionic Acid SCHEMBL11105024 | 0.71 | ESR1 (0.47) | FFAR1ESR1ESR2LMNA | |
| SCHEMBL3548497 | 0.71 | FFAR1 (0.50) | FFAR1KEAP1 | |
| SCHEMBL2285716 | 0.71 | CA2 (0.48) | FFAR1ESR1ESR2LMNA | |
| SCHEMBL3556026 | 0.70 | FFAR1 (0.47) | FFAR1KEAP1ESR1ESR2 | |
| SCHEMBL3553967 | 0.70 | FFAR1 (0.47) | FFAR1KEAP1ESR1ESR2LMNA | |
| Acetic Acid SCHEMBL11105301 | 0.69 | ESR1 (0.47) | FFAR1ESR1ESR2LMNA | |
| SCHEMBL3658988 | 0.66 | CNR1 (0.51) | FFAR1ESR1ESR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1893582-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE IN TREATING METABOLIC DISORDERS | Amgen, Inc (US) | 2008-03-05 | — | — | EP | disclosed |
| WO-2006127503-A2 | COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND METHODS FOR THEIR USE IN TREATING METABOLIC DISORDERS | AMGEN INC (US) | 2006-11-30 | — | — | WO | disclosed |